Short-term anastrozole therapy reduces Ki-67 and progesterone receptor expression in invasive breast cancer: A prospective, placebo-controlled, double-blind trial

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 5, 2011, Pages 897-905

  Mattar, Andre ^a   Logullo, Angela Flávia ^a   Facina, Gil ^a   Nonogaki, Suely ^b   Soares, Fernando Augusto ^c   Gebrim, Luiz Henrique ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO ADOLFO LUTZ   (Brazil)

^c A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

Anastrozole; Breast cancer; Estrogen receptor; Ki 67; Progesterone receptor; Short term hormone therapy

Indexed keywords

ANASTROZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PLACEBO; PROGESTERONE RECEPTOR; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; TAMOXIFEN;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT COURSE THERAPY; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; NITRILES; PROSPECTIVE STUDIES; RECEPTORS, PROGESTERONE; TAMOXIFEN; TRIAZOLES;

EID: 79955702492     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0950-4     Document Type: Article

References (44)

1. Colditz G (1998) Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst 90(11):814-823. doi:10.1093/jnci/90.11.814
2. Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ (2005) Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol 16(11):1723-1739. doi:10.1093/annonc/mdi352
3. Dixon JM, Renshaw L, Bellamy C, Stuart M, Hoctin-Boes G, Miller WR (2000) The effects of neoadjuvant anastrozole (arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin Cancer Res 6(6):2229-2235 (Pubitemid 30399188)
4. Dowsett M (2003) Preoperative models to evaluate endocrine strategies for breast cancer. Clin Cancer Res 9(1):502s-510s
5. Dowsett M (2004) Biomarker investigations from the atac trial: the role of ta01. Breast Cancer Res Treat 87(1):11-18
6. Dowsett M, Dunbier AK (2008) Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res 14(24):8019-8026. doi: 10.1158/1078-0432.ccr-08-0974
7. Dowsett M, Bundred NJ, Decensi A, Sainsbury RC, Lu Y, Hills MJ, Cohen FJ, Veronesi P, O'Brien MER, Scott T, Muchmore DB (2001) Effect of raloxifene on breast cancer cell ki67 and apoptosis. Cancer Epidemiol Biomarkers Prev 10(9):961-966
8. Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, Smith IE (2005a) Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and her-2 in breast cancer-a study from the impact trialists. J Clin Oncol 23(11):2477-2492. doi:10.1200/jco.2005.07.559 (Pubitemid 47050838)
9. Dowsett M, Elizabeth F, Deborah D, Ben H (2005b) The biology of steroid hormones and endocrine treatment of breast cancer. Breast (Edinburgh, Scotland) 14(6):452-457 (Pubitemid 41683566)
10. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G (2005c) Short-term changes in ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 11(2):951s-958s
11. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, A'Hern R (2006) Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin Cancer Res 12(3):1024s-1030s. doi:10.1158/1078-0432.ccr-05-2127
12. Dowsett M, Salter J, Hills M, Detre S, A'Hern R, Smith I (2007) Short-term presurgical treatment for all? Breast Cancer Res 9(Suppl 2):S13
13. EBCTCG (1998) Tamoxifen for early breast cancer: An overview of the randomised trials. The Lancet 351(9114):1451-1467
14. EBCTCG (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. The Lancet 365(9472):1687-1717
15. Ellis M, Ma C (2007) Letrozole in the neoadjuvant setting: The p024 trial. Breast Cancer Res Treat 105:33-43 (Pubitemid 47524802)
16. Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M (2008) Outcome prediction for estrogen receptorpositive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 100(19):1380-1388. doi:10.1093/jnci/djn309
17. Fisher B, Redmond C, Fisher E, Caplan R (1988) Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from national surgical adjuvant breast and bowel project protocol b-06. J Clin Oncol 6(7):1076-1087
18. Geisler J, Detre S, Berntsen H, Ottestad L, Lindtjørn B, Dowsett M, Lønning PE (2001) Influence of neoadjuvant anastrozole (arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res 7(5):1230-1236 (Pubitemid 32708674)
19. Gompel A, Chaouat M, Hugol D, Forgez P (2004) Steroidal hormones and proliferation, differentiation and apoptosis in breast cells. Maturitas 49(1):16-24 (Pubitemid 39209367)
20. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC (2002) Production and actions of estrogens. N Engl J Med 346(5):340-352. doi:10.1056/NEJMra000471
21. Hankinson S, Colditz G, Willett W (2004) Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Res 6(5):213-218
22. Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17(5):1474
23. Hayes D (2008) Markers of endocrine sensitivity. Breast Cancer Res 10(Suppl 4):S18
24. Hengartner MO (2000) The biochemistry of apoptosis. Nature 407(6805):770-776
25. Jager JJ, Jansen RLH, Arends JW (2002) Clinical relevance of apoptotic markers in breast cancer not yet clear. Apoptosis 7(4):361-365 (Pubitemid 34832260)
26. Jensen EV, Jordan VC (2003) The estrogen receptor. Clin Cancer Res 9(6):1980-1989
27. Johnston SRD, Dowsett M (2003) Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer 3(11):821-831 (Pubitemid 37376980)
28. Jordan VC (1994) Molecular mechanisms of antiestrogen action in breast cancer. Breast Cancer Res Treat 31(1):41-52
29. Konstantinidou AE, Korkolopoulou P, Patsouris E (2002) Apoptotic markers for tumor recurrence: a minireview. Apoptosis 7(5):461-470
30. Krajewski S, Krajewska M, Turner B, Pratt C, Howard B, Zapata J, Frenkel V, Robertson S, Ionov Y, Yamamoto H, Perucho M, Takayama S, Reed J (1999) Prognostic significance of apoptosis regulators in breast cancer. Endocr Relat Cancer 6(1):29-40. doi:10.1677/erc.0.0060029 (Pubitemid 29197225)
31. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL (1994) Bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 69(1):135-139 (Pubitemid 24021836)
32. Macaskill EJ, Renshaw L, Dixon JM (2006) Neoadjuvant use of hormonal therapy in elderly patients with early or locally advanced hormone receptor-positive breast cancer. Oncologist 11(10):1081-1088. doi:10.1634/theoncologist.11-10-1081 (Pubitemid 44788399)
33. Miller WR, Anderson TJ, Evans DB, Krause A, Hampton G, Dixon JM (2003) An integrated view of aromatase and its inhibition. J Steroid Biochem Mol Biol 86(3-5):413-421 (Pubitemid 37420005)
34. Molino A, Micciolo R, Turazza M, Bonetti F, Piubello Q, Bonetti A, Nortilli R, Pelosi G, Cetto GL (1997) Ki-67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis. Int J Cancer 74(4):433-437 (Pubitemid 27400164)
35. Musgrove EA, Sutherland RL (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9(9):631-643
36. Pankaj GR, Alastair MT (2006) Cyclin d1 and breast cancer. Breast (Edinburgh, Scotland) 15(6):718-727
37. Pinto AE, André S, Pereira T, Nóbrega S, Soares J (2001) Prognostic comparative study of s-phase fraction and ki-67 index in breast carcinoma. J Clin Pathol 54(7):543-549. doi:10.1136/jcp.54.7.543 (Pubitemid 32642944)
38. Rose C, Vtoraya O, Pluzanska A, Davidson N, Gershanovich M, Thomas R, Johnson S, Caicedo JJ, Gervasio H, Manikhas G, Ayed FB, Burdette-Radoux S, Chaudri-Ross HA, Lang R (2003) An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole. European journal of cancer (Oxford, England: 1990) 39(16):2318-2327
39. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F, Veronesi U (1994) The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86(7):499-504. doi:10.1093/jnci/86.7.499 (Pubitemid 24111005)
40. Silvestrini R, Benini E, Veneroni S, Daidone M, Tomasic G, Squicciarini P, Salvadori B (1996) P53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 14(5):1604-1610 (Pubitemid 26134219)
41. Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med 348(24):2431-2442. doi:10.1056/NEJMra023246 (Pubitemid 36682823)
42. Stendahl M, Kronblad A, Ryden L, Emdin S, Bengtsson NO, Landberg G (2004) Cyclin d1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br J Cancer 90(10):1942-1948 (Pubitemid 38746334)
43. Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A, Coates AS, Collins J, Castiglione-Gertsch M, Gusterson BA (2003) Ki-67 expression in breast carcinoma. Cancer 97(5):1321-1331
44. Whitfield ML, George LK, Grant GD, Perou CM (2006) Common markers of proliferation. Nat Rev Cancer 6 (2):99-106. doi:http://www.nature.com/nrc/ journal/v6/n2/suppinfo/nrc1802-S1.html